Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.45 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904932 | 0.75 | FDPS (0.50) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL4803854 | 0.73 | FDPS (0.44) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL12474925 | 0.71 | FDPS (0.47) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL26660791 | 0.68 | TBXAS1 (0.51) | FDPSTBXAS1CYP11B1CYP11B2ALDH1A1 | |
| Water SCHEMBL5555771 | 0.65 | FDPS (0.43) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1586366 | 0.63 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL19054 | 0.63 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL17124811 | 0.62 | CYP11B1 (0.48) | CA2LMNATBXAS1CYP11B1CYP11B2 | |
| Zoledronic Acid Anhydrous SCHEMBL515095 | 0.62 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1160460 | 0.62 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612050-B2 | Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis | THE ROYAL ALEXANDRA HOSPITAL FOR CHILDREN (AU) | 2009-11-03 | — | — | US | disclosed |
| US-20090005347-A1 | DRUG FOR THE TREATMENT OF OSTEONECROSIS AND FOR THE MANAGEMENT OF PATIENTS AT RISK OF DEVELOPING OSTEONECROSIS | THE SYDNEY CHILDREN'S HOSPITALS NETWORK (RANDWICK AND WESTMEAD) (INCORPORATING THE ROYAL ALEXANDRA HOSPITAL FOR CHILDREN) (AU) | 2009-01-01 | — | — | US | disclosed |
| US-20040157798-A1 | Drug for use in bone grafting | THE ROYAL ALEXANDRA HOSPITAL FOR CHILDREN (AU) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005347-A1 | DRUG FOR THE TREATMENT OF OSTEONECROSIS AND FOR THE MANAGEMENT OF PATIENTS AT RISK OF DEVELOPING OSTEONECROSIS | SOST, BPGM, VDR | FDPS 132/4885GGPS1 318/4885BTN3A1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.